Publications by authors named "Teraoka S"
Importance: Heterogeneity in development of estrogen receptor (ER)-specific first primary breast cancer exists due to deleterious germline variants in moderate- to high-penetrance breast cancer susceptibility genes, but it is unknown if these associations occur in ER-specific CBC.
Objective: To determine the association of deleterious germline variants in breast cancer susceptibility genes with ER-specific CBC development and whether ER status of the first primary breast cancer modifies these associations.
Design, Setting, And Participants: This case-control study included CBC cases and matched unilateral breast cancer controls from The Women's Environment, Cancer, and Radiation Epidemiology (WECARE) Study, a population-based case-control study.
Background: In Japan, since 2014, new treatments such as androgen receptor signaling inhibitors and cabazitaxel have become applicable for metastatic castration-resistant prostate cancer (mCRPC), leading to dramatic changes in treatment options.
Objective: This study aims to evaluate the impact of recent advancements in treatment options on the overall survival (OS) of patients diagnosed with de novo metastatic castration-sensitive prostate cancer (mCSPC) in Japan.
Methods: A retrospective analysis was conducted on 2450 Japanese men diagnosed with de novo mCSPC between 2008 and 2018.
Article Synopsis
- The AminoIndex™ Cancer Screening (AICS breast) test utilizes plasma free amino acid profiles to aid in breast cancer detection, with a study focusing on its correlation with breast density observed through mammograms (MMG).
- Analysis included preoperative mammograms and blood samples from 224 breast cancer patients, showing differing detection rates between MMG and AICS based on breast density classifications.
- The results indicated that while the detection rate for MMG decreased in patients with dense breasts, AICS maintained consistent detection across all breast densities; combining both methods significantly improved overall detection rates.
Introduction: EGFR tyrosine kinase inhibitors have been the standard treatment for patients with NSCLC who have sensitive mutations. This study revealed final analysis survival data, biomarkers, and resistance mechanisms of osimertinib plus bevacizumab or osimertinib monotherapy in previously untreated patients with advanced -positive nonsquamous NSCLC.
Methods: We previously reported the primary results of a randomized, open-label, phase 2 study comparing osimertinib plus bevacizumab with osimertinib monotherapy for this population.
Article Synopsis
- Immune-related adverse events (irAEs) can influence the effectiveness of PD-L1 inhibitors in treating metastatic non-small cell lung cancer (NSCLC), but their impact on nonmetastatic NSCLC outcomes was previously unclear.
- This study evaluated the relationship between irAEs and progression-free survival (PFS) in Stage III NSCLC patients undergoing treatment with the PACIFIC regimen, analyzing both mild and nonmild irAEs through robust statistical methods.
- Findings indicated that patients with nonmild irAEs experienced poorer PFS compared to those with mild irAEs or none at all, suggesting that mild irAEs could indicate better survival outcomes while more severe reactions treated with steroids are linked to worse outcomes.
Background: Mannitol is exclusively recommended in the National Comprehensive Cancer Network guidelines for diuresis in cisplatin (CDDP)-based chemotherapy. The utility of furosemide, a widely used and convenient diuretic, thus requires clarification.
Methods: This is a prospective, single-centered, open-label, noninferiority phase II study.
Article Synopsis
- Lorlatinib showed better effectiveness than crizotinib in a 3-year follow-up study for Japanese patients with advanced NSCLC, aligning with earlier global findings.
- In the study, lorlatinib's median progression-free survival was not reached, while crizotinib had a median of 11.1 months, and the objective response rates were 72.0% for lorlatinib versus 52.2% for crizotinib.
- The safety profile of lorlatinib remained consistent with previous reports, indicating no new safety concerns, and it demonstrated significant benefits for patients with brain metastases.
Background: An association exists among the diagnostic yield of transbronchial biopsy using endobronchial ultrasonography with a guide sheath (EBUS-GS-TBB) and several factors, such as simple within or adjacent endobronchial ultrasonography (EBUS) findings. Here, we aimed to investigate whether more detailed EBUS findings affect the diagnostic yield of lung cancer in EBUS-GS-TBB.
Methods: We conducted this retrospective single-center cohort study, enrolling consecutive patients with lung cancer who underwent EBUS-GS-TBB.
Article Synopsis
- * Results indicate that the combination of AuNPs, cetuximab, and radiotherapy significantly reduces cancer cell numbers and increases apoptosis more effectively than any individual or dual treatments.
- * The findings suggest that while AuNPs do not directly suppress tumors, they enhance the effectiveness of existing treatments without harming normal tissues, making them a promising addition to HNSCC therapy.
Context: The efficacy and tolerability of high-flow nasal cannula (HFNC) for relieving dyspnea in advanced cancer patients with limited prognosis requires elucidation.
Objectives: The primary aim of this trial was to assess the efficacy and tolerability of HFNC regarding dyspnea including severe as well as moderate for longer durations in patients under palliative care.
Methods: In this prospective study, hospitalized patients with advanced cancer who had dyspnea at rest (numeric rating scale, NRS≥3) and hypoxemia were enrolled.
Objectives: To investigate preoperative patient factors that may predict the occurrence of perioperative complications following robot-assisted radical cystectomy at a single center in Japan.
Methods: From 2013 to 2022, 103 patients underwent RARC at our institution. Complications within 90 days after surgery were assessed using the Clavien-Dindo classification.
Article Synopsis
- Actionable genomic alterations, especially EGFR mutations, are found in about 70% of Japanese patients with advanced nonsquamous lung cancer, and standard practice includes quick testing for these mutations as well as ALK and ROS1 fusions.
- A study (WJOG13620L) was conducted to analyze circulating tumor DNA (ctDNA) in patients with untreated advanced lung cancer who tested negative for EGFR mutations using tissue samples, excluding those with other known mutations.
- Out of 72 patients, genetic alterations were found in 29.2% of them, including notable mutations in KRAS, EGFR, and others, with results being available within a median of 8 days; the study suggests that ctDNA
Objective: Although benign, ameloblastoma is a locally aggressive lesion in some patients and the development of additional treatments is needed. Verteporfin (VP) is a photosensitizer exhibiting considerable photocytotoxicity in various tumor cells. We aimed to investigate the effects of verteporfin photodynamic therapy (VP PDT) on ameloblastoma.
View Article and Find Full Text PDFArticle Synopsis
- - The study evaluates the combination of durvalumab immunotherapy and concurrent radiotherapy as a treatment for unresectable, locally advanced non-small cell lung cancer (NSCLC) without using chemotherapy, aiming to improve safety and efficacy over standard concurrent chemoradiotherapy.
- - Conducted in Japan from September 2019 to May 2022, the DOLPHIN trial involved 74 patients with positive PD-L1 status and assessed the 12-month progression-free survival (PFS) rate, which was found to be 72.1% with a median PFS of 25.6 months.
- - Results revealed potential benefits of the treated regimen, with minimal AEs reported, highlighting the efficacy of combining immun
Injuries of the celiac artery and its branches are rare, but potentially lethal. Ligation of these arteries is performed to control significant hemorrhage. However, few reports have described the adverse effects of ligating these arteries.
View Article and Find Full Text PDFArticle Synopsis
- The PACIFIC regimen, which involves durvalumab treatment after chemoradiation, is standard for unresectable stage III NSCLC, but many patients see disease progression within a year, highlighting a need to understand treatment resistance.
- A study involving 135 patients aimed to analyze tumor microenvironments and immune cell profiles to identify resistance mechanisms, revealing key findings related to adaptive immunity and specific cancer cell behaviors.
- Results showed that low levels of CD8 lymphocytes and high CD73 expression in tumors correlate with poor treatment outcomes, suggesting that targeting CD73 may improve future therapies and highlighting the role of adaptive immunity in treatment effectiveness.
Introduction: Circulating tumor DNA (ctDNA) has been used as a biomarker for prognostication and response to treatment. Here, we evaluate ctDNA as a potential biomarker for response to lorlatinib, a third-generation ALK tyrosine kinase inhibitor in patients with treatment-naive, advanced, ALK-positive NSCLC in the ongoing phase 3 CROWN study (NCT03052608).
Methods: Molecular responses were calculated using mean variant allele frequency (VAF), longitudinal mean change in VAF (dVAF), and ratio to baseline.
Introduction: Lorlatinib is a potent, third-generation inhibitor of ALK. In the planned interim analysis of the ongoing, phase 3, randomized, global CROWN trial (NCT03052608), lorlatinib resulted in significantly longer progression-free survival than crizotinib in patients with previously untreated, advanced, -positive NSCLC. Here, we present a subgroup analysis of Asian patients in the CROWN study.
View Article and Find Full Text PDF[Robotic-Assisted Surgery for Renal Cancer and Cancer of the Renal Pelvis and Ureter].
Gan To Kagaku Ryoho
April 2023
Recently, minimally invasive urological surgery has become increasingly common as years pass, with the rapid development of laparoscopic, minimal wound, mono-sectional, and robot-assisted surgeries. Robot-assisted surgery's indication for renal, renal pelvis, and ureter cancers has been expanded, and in Japan, robot-assisted partial nephrectomy(RAPN)has been covered by insurances since 2016. Additionally, robot-assisted radical nephrectomy(RARN)and robot-assisted nephroureterectomy(RANU)were covered by insurances in 2022.
View Article and Find Full Text PDFIntroduction: Lorlatinib, a third-generation ALK inhibitor, was found to have improved efficacy versus crizotinib in patients with previously untreated, advanced -positive NSCLC in the ongoing, global, randomized, phase 3 CROWN study.
Methods: The study's primary end point was progression-free survival assessed by blinded independent central review. Secondary end points included objective and intracranial response.
Background/aim: There are few reports confirming the relationship between the therapeutic effects of adjuvant systemic chemotherapy and intravesical recurrence after radical nephroureterectomy for upper urinary tract urothelial carcinoma. We aimed to evaluate the benefits of adjuvant systemic chemotherapy on intravesical recurrence after radical nephroureterectomy for upper urinary tract urothelial carcinoma.
Patients And Methods: We retrospectively reviewed the medical records of 133 patients with pathological T stage ≥3 upper urinary tract urothelial carcinoma or lymph node metastasis who underwent radical nephroureterectomy between January 2010 and September 2020 at our hospital and other satellite hospitals.
Article Synopsis
- The study focused on developing and validating a scale to help public health nurses support community-building among resident groups in Japan.
- A total of 1,924 public health nurses participated by completing questionnaires, which were analyzed statistically to assess the scale's reliability and validity.
- The final scale comprised 30 items across four factors and demonstrated high reliability (Cronbach's alpha of 0.944) and validity, confirming its usefulness for public health nurses.
Platelet-rich plasma (PRP) and adipose-derived stem cells (ADSCs) are known to secrete angiogenic factors that contribute to the treatment of intractable ulcers. The combination of PRP and ADSCs may enhance their angiogenic effects. However, it remains unclear whether treatment of ADSCs with PRP influences angiogenesis.
View Article and Find Full Text PDFBackground: Conquering acquired resistance to osimertinib remains a major challenge in treating patients with epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC). Thus, we aimed to determine the safety and efficacy of combination treatment with osimertinib and afatinib for patients with acquired resistance to osimertinib.
Methods: This open-label phase I study was a feasibility study of the combination of afatinib and osimertinib for patients with advanced EGFR-positive NSCLC who had progressive disease after receiving osimertinib.
Background/aim: Postoperative urinary incontinence (UI) after robot-assisted radical prostatectomy (RARP) has a significant impact on patients' quality of life (QOL). Several surgical techniques have been reported to improve postoperative UI. The aim of the study was to investigate the impact of advanced reconstruction of vesicourethral support (ARVUS) on urinary symptoms and QOL after non-nerve-sparing robot-assisted radical prostatectomy (RARP).
View Article and Find Full Text PDF